erlotinib hydrochloride has been researched along with Intestinal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PH; Dashwood, RH; Dashwood, WM; Gustafson, TA; Kapoor, S; Mohammed, A; Rajendran, P; Savage, MI; Sei, S; Ulusan, AM; Vilar, E; Yavuz, OF | 1 |
| Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Taketo, MM | 1 |
2 other study(ies) available for erlotinib hydrochloride and Intestinal Neoplasms
| Article | Year |
|---|---|
Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Topics: Adenomatous Polyposis Coli; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonic Polyps; Disease Models, Animal; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Genes, APC; Intestinal Neoplasms; Male; Mutation; Rats; Sulindac | 2021 |
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Intestinal Neoplasms; MAP Kinase Signaling System; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2017 |